Fight Colorectal Cancer Launches its Plan to Find a Cure
January 18, 2022 14:40 ET | Fight Colorectal Cancer
Springfield, Mo., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Today, Fight Colorectal Cancer (Fight CRC), the nation's leading patient advocacy organization,  revealed its Path to a Cure Report for colorectal...
biomerica.png
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
January 13, 2022 08:19 ET | Biomerica, Inc.
Revenues up 239% over prior year fiscal second quarter  Customer orders backlog of over $4.0 million at November 30, 2021  Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...
22157.jpg
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
January 05, 2022 06:38 ET | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
biomerica.png
Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening
November 19, 2021 08:19 ET | Biomerica, Inc.
Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at HoustonScientific Advisory Board to guide on programs to screen and test patients in US...
biomerica.png
Walmart to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Screening Test
October 19, 2021 06:39 ET | Biomerica, Inc.
Over 4,600 Walmart Stores to sell the EZ Detect™ productSimple 2 minute at-home test detects early warning sign of colorectal cancer IRVINE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) --...
biomerica.png
Walmart Now Selling Biomerica’s EZ Detect™ Colorectal Screening Test
October 01, 2021 06:39 ET | Biomerica, Inc.
Simple 2 minute at-home test detects early warning sign of colorectal cancer IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced...
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
October 01, 2021 02:00 ET | BioNTech SE
Second Phase 2 trial initiated from BioNTech’s proprietary individualized mRNA-based cancer vaccine platform iNeST Randomized Phase 2 trial will enroll approximately 200 patients with high-risk...
BioNTech erweitert klinisches Onkologie-Portfolio: Erster Patient in Phase 2-Studie mit individualisierter mRNA-basierter Immuntherapie BNT122 gegen Darmkrebs behandelt
October 01, 2021 02:00 ET | BioNTech SE
Zweite Phase-2-Studie initiiert, die auf BioNTechs unternehmenseigener individualisierter mRNA-basierten Krebsimpfstoff-Plattform iNeST basiert Randomisierte Phase-2-Studie wird rund 200 Patienten mit...
Hundreds of Cancer Survivors and Caregivers from Across the Country to Climb for a Cure
August 17, 2021 17:44 ET | Fight Colorectal Cancer
Springfield, Mo., Aug. 17, 2021 (GLOBE NEWSWIRE) -- National nonprofit organization Fight Colorectal Cancer (Fight CRC) is hosting its annual hiking event on August 22, 2021, to raise awareness and...
logo.gif
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
July 06, 2021 09:00 ET | Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...